Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review.

BridgeBio Pharma (NasdaqGS:BBIO) reports recent clinical and regulatory milestones across late-stage rare disease assets, including acoramidis, BBP-418, and encaleret. Acoramidis continues to show differentiated efficacy signals in ATTR-CM based on recent late-phase data and real-world findings. BBP-418 for LGMD2I/R9 and encaleret for ADH1 each receive Priority Review status, with BBP-418 positioned as a first potential therapy for its indication. Recent progress supports BridgeBio Pharma’s...

The company clearly has a winner on its hands with the recently approved Attruby.

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poi

BBIO's Q2 loss misses estimates, but revenues beat expectations as Attruby sales more than tripled, fueling growth and pipeline advances.

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

BridgeBio Pharma Inc (BBIO) posts record $243.7M quarterly revenue, driven by Attruby's explosive growth and a $1B financing boost, while advancing three FDA-accepted NDAs toward a pivotal 2027.

Moby summary of BridgeBio Pharma, Inc.'s Q2 2026 earnings call

BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review and expanding commercial preparations for potential launches over the next year. Chief Executive Off

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.88% and +9.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

VTRS readies Q2 results as growth in key markets and brands may offset manufacturing and pricing headwinds across parts of its portfolio.

BridgeBio Pharma stock has delivered a very strong 147.9% return over the past three years, yet its current checks lean expensive rather than clearly cheap. With a key drug candidate progressing through the US approval process and the valuation screen showing a low score, investors are weighing how much of the story is already reflected in the price. The 147.9% three year return highlights how much optimism has already been priced into BridgeBio Pharma. The FDA acceptance of the New Drug...

The FDA has accepted BridgeBio Pharma's New Drug Application for encaleret for autosomal dominant hypocalcemia type 1. The filing includes pivotal trial data for a potential first approved therapy that targets the underlying genetic cause of ADH1. The agency has assigned a target action date, starting the formal review process for encaleret. BridgeBio Pharma, traded as NasdaqGS:BBIO, now has a key regulatory file under active FDA review with encaleret for ADH1. The stock closed at $79.96,...

Why BridgeBio Pharma Stock Is Back In Focus BridgeBio Pharma (BBIO) is back on investor radars after filing two shelf registrations totaling about US$2.21b in common stock, alongside detailed updates on its late stage encaleret program for ADH1 and chronic hypoparathyroidism. See our latest analysis for BridgeBio Pharma. BridgeBio Pharma shares trade at US$80.09 after a recent 1 day share price return that declined 2.5%, although the 3 month share price return of 16.82% and 1 year total...

Rapid commercial momentum could justify Wall Street's bullish outlook.

The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.

13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.